Parietal Cell Regulation
Parietal Cell Regulation - Related Videos
01:28
pH Regulation in Cells
0 Views •
2023
pH plays a critical role in maintaining normal cellular activities. It helps maintain the structure and function of various proteins, dictates the charge on cellular membranes, and is crucial for metabolic reactions inside the cell. Moreover, cells use the energy from the proton motive force to generate ATP. Cytosolic pH Under physiological conditions, the cytosolic pH is slightly more acidic than the extracellular pH. However, cells must prevent further acidification of their cytosol to...
16:24
Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells
0 Views •
Cited by 9 •
2014
Molecular signaling through both estrogen and microRNAs are critical in breast cancer development and growth. Estrogen activates the estrogen receptors, which are transcription factors. Many transcription factors can regulate the expression of microRNAs, and estrogen-regulated microRNAs can be profiled using different large-scale techniques.
06:39
Glomerular Outgrowth as an Ex Vivo Assay to Analyze Pathways Involved in Parietal Epithelial Cell Activation
0 Views •
2020
This article describes a method for culturing and analyzing glomerular parietal epithelial cell outgrowths of encapsulated glomeruli isolated from mouse kidney. This method can be used to study pathways involved in parietal epithelial cell proliferation and migration.
10:43
siRNA Screening to Identify Ubiquitin and Ubiquitin-like System Regulators of Biological Pathways in Cultured Mammalian Cells
0 Views •
Cited by 4 •
2014
Here, we describe a methodology to perform a targeted siRNA “ubiquitome” screen to identify novel ubiquitin and ubiquitin-like regulators of the HIF1A-mediated cellular response to hypoxia. This can be adapted to any biological pathway where a robust read out of reporter activity is available.
01:46
Epigenetic Regulation
0 Views •
2019
Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer. In most mammals, females have two X chromosomes (XX) while males have an X and a Y chromosome (XY). The X chromosome contains significantly more genes than the Y chromosome. Therefore, to prevent an excess of X chromosome-linked gene expression in females, one of the two X chromosomes is randomly silenced during early development.
FAQs
These three stimulatory signals act through complementary pathways rather than functioning as interchangeable triggers. Gastrin provides hormonal input, acetylcholine supplies neural input, and histamine contributes local signaling. Their combined activity converges on the H+/K+-ATPase proton pump, allowing acid output to reflect the integrated state of neural, hormonal, and local regulatory systems.
Somatostatin provides an inhibitory counterbalance to stimulatory signals from gastrin, acetylcholine, and histamine. By suppressing secretion, it contributes to local feedback control and prevents acid output from being determined solely by activating pathways. This opposing influence helps explain why gastric acidity changes according to the balance between stimulation and inhibition rather than one signal alone.
The H+/K+-ATPase represents a final point at which several stimulatory pathways promote acid secretion. Targeting this proton pump can therefore reduce gastric acidity even when upstream signals remain active. Its position within the regulatory system makes it especially important for pharmacological strategies aimed at controlling acid-related disease and altering the overall secretory outcome.
Both drug classes reduce gastric acidity, but they act at different levels of the regulatory network. Proton pump inhibitors target the H+/K+-ATPase, the final secretory machinery, whereas histamine H2-receptor antagonists interfere with histamine-mediated stimulation upstream. This distinction helps pharmacology address acid secretion either at its common endpoint or through one specific activating pathway.
Assessment should account for the major stimulatory inputs, the inhibitory influence of somatostatin, and the proton pump that integrates these signals into acid output. It should also consider intrinsic factor secretion and the possibility that reducing gastric acidity may affect nutrient absorption. This broader view links drug action with gastric physiology rather than measuring acidity alone.
Acid-reducing pharmacology is relevant in conditions such as peptic ulcer disease and gastroesophageal reflux. Treatment can focus on limiting the final proton-pump step or blocking histamine-dependent stimulation, depending on the therapeutic strategy. Understanding the underlying regulation helps connect these drug actions with the goal of reducing excessive gastric acidity.
Gastric acid secretion contributes to the digestive environment, while parietal cells also secrete intrinsic factor. Consequently, pharmacological suppression of acid output must be considered in the context of both secretory functions and their relationship to nutrient absorption. This connection explains why acid-reducing therapy requires attention not only to symptom control but also to broader gastric physiology.